Loading company
Cellectis S.A.
CLLS · Nasdaq · ·
Next earnings: November 6, 2026
$1.47-1.0%Sep 29 close
- 1M
- -56.8%
- 6M
- -52.6%
- 1Y
- -48.4%
- 5Y
- -89.1%
CLLS · Nasdaq · ·
Next earnings: November 6, 2026
$1.47-1.0%Sep 29 close
Cellectis S.A. is scheduled to report next on November 6, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2025, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2025 | 3 months toDec 31, 2021 | Change |
|---|---|---|---|
| Total Revenue | $16.7M | $1.9M | +760.78% |
| Profit | -$23.7M | -$11.7M | -102.75% |
| Profit per share | -$0.24 | -$0.20 | -20.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Cellectis S.A. has no earnings call transcript available.
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Cellectis S.A. filed on August 6, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.